The payment was received by year-end 2018. This scientific achievement was the advancement of a program into the lead optimization stage developed from Evotec’s compound library using its induced pluripotent stem cell (“iPSC”)-based screening platform. This program can be further optimized and progressed towards IND-ready status.  

 

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s unique human iPSC technology platform, which is one of the largest platforms in the industry.  

 

Dr Cord Dohrmann, chief scientific officer of Evotec, said, “We are very proud of the success achieved in our collaboration with Celgene, which we believe validates our iPSC approach and is a testament to a highly productive collaboration. I would like to congratulate the teams from both companies on the excellent progress and wish them continued success moving forward.”